Bio Pharma Dive
JUNE 11, 2024
The medicine will join Intercept’s Ocaliva as a treatment option for primary biliary cholangitis. Another drug, from the now Gilead-owned CymaBay, could be cleared for the condition by August.
Pharmaceutical Technology
JUNE 11, 2024
AstraZeneca's sNDA for Tagrisso has obtained FDA priority review for unresectable, Stage III EGFRm non-small cell lung cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JUNE 11, 2024
Newer components and drug combinations could expand use of the targeted cancer medicines, according to company executives.
Rethinking Clinical Trials
JUNE 11, 2024
Dr. Andrea Cook and Dr. Lynn DeBar, principal investigators of BackInAction Many older adults who participate in acupuncture research may have prior experience with acupuncture, according to an analysis of data from the BackInAction trial. The finding has implications for the design and conduct of future pragmatic clinical trials involving acupuncture.
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.
Bio Pharma Dive
JUNE 11, 2024
After an FDA panel backed the experimental Lilly drug, Wall Street analysts see its likely clearance as benefiting Eisai and Biogen’s rival Leqembi.
Pharma Times
JUNE 11, 2024
Alzheimer’s and Parkinson’s disease are responsible for more than 30 million cases globally
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Fierce Pharma
JUNE 11, 2024
Right after signing on to help with bird flu pandemic preparedness efforts in the U.S., CSL Seqirus has agreed to do the same in Europe through a vaccine supply pact. | The vaccine maker will deliver 665,000 doses of its avian flu-matched pre-pandemic vaccine. Under a 4-year contract, authorities can purchase up to 40 million doses.
Pharma Mirror
JUNE 11, 2024
By Michael von Papen, Chief Expert at Pharmatec GmbH – a Syntegon Company When a leading global collagenase manufacturer wants to renew and optimize a system at the heart of its production, technical expertise, and engineering competence is paramount. Moreover, cooperation within the project team needs to be well organized. Nordmark and Pharmatec, a subsidiary of Syntegon, have shown how this helps to master even unexpected challenges during the construction of a new filtration and concent
Pharmaceutical Technology
JUNE 11, 2024
Early diagnosis of chronic kidney disease has both economic and environmental benefits, according to AstraZeneca’s Mina Makar.
Fierce Pharma
JUNE 11, 2024
Amid a recent biopharma M&A resurgence, one major player plans to stay out of the waters after making multiple recent splashes. | Though not for lack of business development capacity, Pfizer is currently taking a large dealmaking “breathing period,” CEO Albert Bourla told investors this week at Goldman Sachs’ 2024 annual Global Healthcare Conference in Miami.
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
Pharmaceutical Technology
JUNE 11, 2024
The funds will be used to advance PD1-IL18 immunoconjugate BPT567 into early-stage trials for solid tumours.
pharmaphorum
JUNE 11, 2024
Get the latest updates on clinical trials from 3rd to 7th June involving companies like uniQure, Takeda, Otsuka, CatalYm, Agios, and Transgene. Stay informed on the latest developments in the field.
Pharmaceutical Technology
JUNE 11, 2024
Experts highlighted the need to address a gap in UK regulatory timelines compared to international standards.
pharmaphorum
JUNE 11, 2024
The FDA is exploring ways to transform the home into a healthcare hub, bringing healthcare services closer to individuals. This article discusses the potential impact of this trend on the future of healthcare.
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
Pharmaceutical Technology
JUNE 11, 2024
Cancer-focused biotech Tacalyx has extended its seed financing round to raise over €14m ($15.03m).
pharmaphorum
JUNE 11, 2024
An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busting drug support its approval. The independent advisors on the Peripheral and Central Nervous System Drugs Advisory Committee voted by 11 to zero that donanemab’s benefits outweigh its risks, and by the same margin that the data submitted by Lilly to support its efficacy was convincing.
Pharmaceutical Technology
JUNE 11, 2024
Protect AAV viral particles with Ultragenyx's patented heat inactivation method. Learn how specific buffers preserve genomic integrity and biological activity.
pharmaphorum
JUNE 11, 2024
The FDA's Single Institutional Review Board (sIRB) mandate is good news for clinical research. Learn more about how this mandate benefits everyone involved in the clinical research process.
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
Pharmaceutical Technology
JUNE 11, 2024
Discover Purdue Pharma's innovative tamper-resistant opioid analgesic dosage form with extended release properties. Learn about the patented solid oral form designed for controlled drug release and enhanced safety in medication administration.
pharmaphorum
JUNE 11, 2024
Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).
Pharmaceutical Technology
JUNE 11, 2024
Discover Kineta Inc's groundbreaking patent for compounds targeting proteostasis dysfunction. Learn about the specific chemical structures, pharmaceutical compositions, and methods for treating various conditions, including cancer symptoms. US Patent Publication Number: US11958873B2.
pharmaphorum
JUNE 11, 2024
CSL Seqirus will provide 665,000 doses of bird flu vaccine to the European Commission to protect at-risk workers and guard against a potential outbreak
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharmaceutical Technology
JUNE 11, 2024
Discover a patented method for removing contaminant material from oil and gas industrial equipment using a unique solvent composition. Learn more about this innovative approach in the recently granted patent US11946021B2.
Fierce Pharma
JUNE 11, 2024
As Gilead Sciences awaits the progression of California state litigation over its alleged delay of safer HIV drugs, the company is biding its time with a proposed $40 million settlement t | More than 2,000 plaintiffs accused the HIV drugmaker of purposely waiting to launch safer TAF-based meds in the early 2000s in order to maximize profits from its older TDF-based products.
Pharmaceutical Technology
JUNE 11, 2024
Discover how Syros Pharmaceuticals' patented compounds inhibit CDK7, inducing cellular apoptosis and treating diseases like cancer and ALS.
pharmaphorum
JUNE 11, 2024
In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of such treatment, with Rafael R Carazo Salas, founder and CEO of CellVoyant, an AI-first biotechnology company spun out from the University of Bristol.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
JUNE 11, 2024
Discover the groundbreaking patent by Silence Therapeutics Plc for a compound revolutionizing RNA interference therapy. Learn how formula (II) is paving the way for targeted treatment of liver disease and genetic disorders.
pharmaphorum
JUNE 11, 2024
The Association of the British Pharmaceutical Industry (ABPI) is calling on political parties contesting the general election to spell out their plans to nurture and drive growth in the life sciences sector and deliver for patients.
Pharmaceutical Technology
JUNE 11, 2024
Reduce blood phenylalanine levels in adolescents with PKU using AvPAL variants. A detailed patent outlines a method involving weekly doses over 50 weeks for subjects aged 12-17, with dosage adjustments for optimal results.
Fierce Pharma
JUNE 11, 2024
Once hyped as a potential blockbuster medicine for metabolic-associated steatohepatitis (MASH), Ipsen and Genfit’s elafibranor has found its calling as a treatment for a lower-profile liver disorde | Once hyped as a potential blockbuster medicine for metabolic-associated steatohepatitis (MASH), Ipsen and Genfit’s elafibranor has found its calling as a treatment for a lower-profile liver disorder.
Expert insights. Personalized for you.
284 
Let's personalize your content